Scientist II, Bioinformatics
Mammoth Brisbane, CA /
2100 - Therapeutics – R&D - Therapeutics /
Mammoth is seeking a Bioinformatics Scientist II to join its growing team. The successful candidate will contribute towards Mammoth’s efforts to develop safe and effective therapeutic treatments for genetic diseases. The Scientist II, Bioinformatics will work closely with researchers, development teams and external partners to establish statistical analysis tools, help design assays and produce insights on the effects of our novel CRISPR systems. The scientist will also interact closely with the computational team to define and use internal tooling.
- Design statistical analysis pipelines for multi-omics data
- Work closely with the platform team to help optimize our novel CRISPR system
- Communicate your solutions to a team of software and data engineers
- Organize and present data in internal and external meetings
- Other duties as assigned
- PhD with 1+ years of experience, MS with 4+ years of experience, or BS with 6+ years of experience in Computer Science, Bioinformatics, Computational Biology, Biostatistics, or a related field
- Experience in developing bioinformatic pipelines
- Proficiency in Python and SQL
- Experience designing multi component high throughput experiments
- Experience working with cloud resources in AWS
- Experience communicating and visualizing results to computational and scientific teams
- Experience analyzing CRISPR related assays
- Proficiency in R
- Experience working with modeling lab assays with LIMS system
- Experience working with workflow management systems (Prefect, Airflow, Nextflow)
- Experience writing code in a production environment (CI/CD, testing)
- Company-paid health/vision/dental benefits
- Unlimited vacation and generous sick time
- Company-sponsored meals and snacks
- Wellness, caregiver and ergonomics benefits
- 401(k) with company matching
Mammoth Biosciences is harnessing the diversity of life to power the next generation of CRISPR products. Through the discovery and engineering of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth aims to develop permanent genetic cures through best-in-class in vivo and ex vivo therapies and to democratize disease detection with on-demand diagnostics. Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in the San Francisco Bay Area, Mammoth Biosciences is co-founded by CRISPR pioneer and Nobel Laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Redmile Group, Foresite Capital, Senator Investment Group, Sixth Street, Decheng, Mayfield, NFX, and 8VC, along with leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.
Our small-size proteins, such as Cas14 and CasPhi, are poised to transform disease treatment enabling novel editing approaches and delivery options that are difficult to achieve or not even possible with previously described CRISPR-Cas systems. Our teams are responsible for discovering and engineering novel CRISPR systems, establishing CRISPR-based diagnostics, and translating our unique CRISPR technology into therapeutic treatments with the ultimate goal of cures for indications with high medical need.
It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law. This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.
Mammoth Biosciences requires that all employees be vaccinated against COVID-19 as a condition of at-will employment, with exceptions for medical or religious reasons in compliance with local, state, and federal law.